Ramucirumab
Reading tools
Another drug approved by the FDA on 12 December 2014 is Cryamza. It began being used for advanced (metastatic) non-small cell lung cancer, the most common lung cancer type. Cryamza blocks formation of new vessels feeding the tumor. Combining it with other chemotherapy drugs proven effective in lung cancer, such as docetaxel, was found beneficial. Side effects such as high blood pressure and diarrhea were observed.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.